Fig. 1

Overview of the efficacy of Bruton’s tyrosine kinase inhibitors (BTKi) in the treatment of 10 patients with vitreoretinal lymphoma. A Best-corrected visual acuity (BCVA) comparison between baseline and during follow-up with red lines indicating the mean and 95% confidence interval. B Interleukin (IL)-10 levels in aqueous humor at baseline and during follow-up with red lines showing the median and 95% confidence interval. C Overall survival (OS). D Progression-free survival (PFS). E Swimlane flowcharts illustrating the detailed efficacy information. Of the 10 patients, 7 achieved complete response (CR), 2 achieved partial response (PR), and one (#4) experienced central nervous system (CNS) progression after one-month BTKi treatment. Until the last follow-up, 2 of the 9 patients with disease control developed ocular relapse (#1 and #2), and 2 developed CNS progression (#2 and #5). The remaining 6 patients have durable response. *P < 0.05, **P < 0.01